These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14511765)

  • 21. Heparin binding site, conformational change, and activation of antithrombin.
    Evans DL; Marshall CJ; Christey PB; Carrell RW
    Biochemistry; 1992 Dec; 31(50):12629-42. PubMed ID: 1366018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heterogeneity of recombinant human antithrombin III expressed in baby hamster kidney cells. Effect of glycosylation differences on heparin binding and structure.
    Fan B; Crews BC; Turko IV; Choay J; Zettlmeissl G; Gettins P
    J Biol Chem; 1993 Aug; 268(23):17588-96. PubMed ID: 8349638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Energetics of hydrogen bond switch, residue burial and cavity analysis reveals molecular basis of improved heparin binding to antithrombin.
    Singh P; Singh K; Jairajpuri MA
    J Biomol Struct Dyn; 2011 Oct; 29(2):339-50. PubMed ID: 21875153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem J; 1988 Sep; 254(2):547-51. PubMed ID: 2902851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-function relations of antithrombin III-heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide-pentasaccharide-docked complexes.
    Tyler-Cross R; Sobel M; McAdory LE; Harris RB
    Arch Biochem Biophys; 1996 Oct; 334(2):206-13. PubMed ID: 8900394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa.
    Lin P; Sinha U; Betz A
    Biochim Biophys Acta; 2001 Apr; 1526(1):105-13. PubMed ID: 11287128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of heparin with two synthetic peptides that neutralize the anticoagulant activity of heparin.
    Wang J; Rabenstein DL
    Biochemistry; 2006 Dec; 45(51):15740-7. PubMed ID: 17176096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Probing the molecular basis of factor Xa specificity by mutagenesis of the serpin, antithrombin.
    Rezaie AR; Yang L
    Biochim Biophys Acta; 2001 Oct; 1528(2-3):167-76. PubMed ID: 11687304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromatography of heparin on sepharose-lysine: molecular size fractionation and its relevance to thrombin and antithrombin III binding.
    Hatton MW; Berry LR; Kaur H; Koj A; Regoeczi E
    Can J Biochem; 1979 Oct; 57(10):1183-90. PubMed ID: 120212
    [No Abstract]   [Full Text] [Related]  

  • 30. Non-specific influence of chemical modification upon the properties of antithrombin III:modification of carboxyl groups.
    Scully MF; Kakkar VV; Goodwin CA
    Thromb Res; 1992 Aug; 67(4):447-56. PubMed ID: 1412223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics.
    Masuko S; Linhardt RJ
    Future Med Chem; 2012 Mar; 4(3):289-96. PubMed ID: 22393937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change.
    Turk B; Brieditis I; Bock SC; Olson ST; Björk I
    Biochemistry; 1997 Jun; 36(22):6682-91. PubMed ID: 9184148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.
    Chang LC; Liang JF; Lee HF; Lee LM; Yang VC
    AAPS PharmSci; 2001; 3(3):E18. PubMed ID: 11741269
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression and characterization of recombinant human antithrombin III in Pichia pastoris.
    Mochizuki S; Hamato N; Hirose M; Miyano K; Ohtani W; Kameyama S; Kuwae S; Tokuyama T; Ohi H
    Protein Expr Purif; 2001 Oct; 23(1):55-65. PubMed ID: 11570846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation and characterization of a heparin with high anticoagulant activity from the clam Tapes phylippinarum: evidence for the presence of a high content of antithrombin III binding site.
    Cesaretti M; Luppi E; Maccari F; Volpi N
    Glycobiology; 2004 Dec; 14(12):1275-84. PubMed ID: 15253929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components.
    Schroeder M; Hogwood J; Gray E; Mulloy B; Hackett AM; Johansen KB
    Anal Bioanal Chem; 2011 Jan; 399(2):763-71. PubMed ID: 20922518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A heparin-binding synthetic peptide of heparin/heparan sulfate-interacting protein modulates blood coagulation activities.
    Liu S; Zhou F; Höök M; Carson DD
    Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1739-44. PubMed ID: 9050848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Protamine complexes with antithrombin III and heparin].
    Roszkowska W; Worowski K
    Acta Haematol Pol; 1982; 13(1-2):25-8. PubMed ID: 7180353
    [No Abstract]   [Full Text] [Related]  

  • 39. Antimicrobial effects of helix D-derived peptides of human antithrombin III.
    Papareddy P; Kalle M; Bhongir RK; Mörgelin M; Malmsten M; Schmidtchen A
    J Biol Chem; 2014 Oct; 289(43):29790-800. PubMed ID: 25202017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of a heparan sulphate with high affinity for antithrombin III upon inactivation of thrombin and coagulation factor Xa.
    Scully MF; Ellis V; Shah N; Kakkar V
    Biochem J; 1989 Sep; 262(2):651-8. PubMed ID: 2529852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.